scholarly journals Spermatogenic and sperm quality differences in an experimental model of metabolic syndrome and hypogonadal hypogonadism

Reproduction ◽  
2011 ◽  
Vol 142 (1) ◽  
pp. 63-71 ◽  
Author(s):  
Con Mallidis ◽  
Agnieszka Czerwiec ◽  
Sandra Filippi ◽  
Jason O'Neill ◽  
Mario Maggi ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Blood Glucose ◽  
Advanced Glycation End Products ◽  
Nuclear Dna ◽  
Sperm Quality ◽  
Moderate Increase ◽  
Advanced Glycation ◽  
Male Reproductive Function ◽  
Glycation End Products ◽  
End Products

The synergistic effect of the co-morbidities that comprise metabolic syndrome (MetS) is increasingly being recognised as an important contributor in the pathology of a broad spectrum of seemingly disparate conditions. However, in terms of male reproductive function, beyond erectile dysfunction, little is known about the influence of this cohort (collectively or separately) on spermatogenesis and sperm quality. The aims of this study were to assess the reproductive tract of a MetS animal model for detrimental changes, to determine whether a group of compounds (advanced glycation end products and their receptor) known to cause cell dysfunction and DNA damage was present and assess whether hypogonadotropic hypogonadism was the main contributing factor for the changes seen. Animals fed a high-fat diet were found to have significantly increased cholesterol, triglycerides, blood glucose, mean arterial pressure and visceral fat levels. Although serum testosterone was decreased, no changes were seen in either testicular or epididymal histology. Immunolocalisation ofNϵ-carboxymethyl-lysine and the receptor for advanced glycation end products was found in the testes, epididymides and sperm of the two treated groups of animals; however, ELISA did not show any difference in protein levels. Similarly, assessment of sperm nuclear DNA (nDNA) fragmentation by acridine orange test did not find significant differences in nDNA integrity. We conclude that the minimal effect on spermatogenesis and sperm quality seen in our model is probably due to the moderate increase of blood glucose rather than the hypogonadism.

scholarly journals Association of Dietary Advanced Glycation End Products with Metabolic Syndrome in Young Mexican Adults

Medicines ◽  
2018 ◽  
Vol 5 (4) ◽  
pp. 128 ◽  
Author(s):  
Kenny Mendoza-Herrera ◽  
Celia Aradillas-García ◽  
Miguel Mejía-Diaz ◽  
Jorge Alegría-Torres ◽  
Ma. Garay-Sevilla ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Family History ◽  
Energy Intake ◽  
Advanced Glycation End Products ◽  
Fasting Glucose ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
History Of ◽  
Mexican Adults

Background: Consumption of dietary advanced glycation end products is linked to metabolic syndrome. The objective was to describe the association between dietary advanced glycation end products intake and metabolic syndrome in young Mexican adults. Methods: The present was a cross-sectional study in 126 Mexican adults 18–35 years old evaluating metabolic syndrome through the harmonized criteria. Macronutrients and dietary advanced glycation end products intake were estimated through three 24-hour dietary recalls and food composition tables. Association between metabolic syndrome and high advanced glycation end products intake (≥10,000 kU/day) was evaluated through three logistic regression models adjusted by sex, age, family history of cardiometabolic diseases and energy intake. Results: Subjects with a higher advanced glycation end products intake were more likely to have impaired fasting glucose (OR: 4.91, 95% CI 1.29–18.60, p < 0.05) and metabolic syndrome (OR: 2.67, 95% CI 0.96–7.44, p = 0.059) than those participants with low consumption of these products after adjustment of sex, age, family history of cardiovascular disease and energy intake. Conclusions: High intake of dietary advanced glycation end products was significantly associated with impaired fasting glucose and marginally with metabolic syndrome in young Mexican adults regardless of sex, age, family history of cardiovascular disease and energy intake.

scholarly journals Glucose Lowering Effect of Basil Leaves in Diabetic Rats

2019 ◽  
Vol 7 (9) ◽  
pp. 1415-1417 ◽  
Author(s):  
Sry Suryani Widjaja ◽  
Rusdiana ◽  
Maya Savira
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Blood Glucose Level ◽  
Glucose Level ◽  
Advanced Glycation End Products ◽  
Diabetic Rats ◽  
Diabetic Group ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

BACKGROUND: The incidence of diabetes and its complications has risen since the last decades, and it has been predicted that the prevalence of diabetes will be double in the coming year. Chronic hyperglycemia marked as elevated advanced glycation end products plays an important role in complications of diabetes. Basil leaves (Ocimum basilicum) originating from India and commonly found in Southeast Asia, is widely used empirically to decrease the blood sugar in diabetic patients. AIM: The purpose of the study was to investigate the effect of extract ethanol of Basil leaves in diabetic rats. METHODS: This is an experimental study; Streptozotocin was used to induce type 2 diabetic rats. Thirty Wistar male rats were divided into six groups (normal group, group treated with metformin 45 mg/kg body weight, group treated with Basil leaves 100 mg/kg body weight, 200 mg/kg body weight, 400 mg/kg body weight, control diabetic group). The blood glucose level was measured before induction and after treatment at week 1 and 4. Advanced glycation end products were measured in all groups at week 4. RESULTS: Extract ethanol of basil leaves 100, 200, 400 mg/body weight all showed significant lowering blood glucose level (p < 0.001) compared to diabetic group without treatment, but did not show superior to metformin group (p = 0.17), advanced glycation end products did not show statistical significance between group with normal rats and group of diabetic rats treated with basil leaves 100 mg/kg, 200 mg/kg, 400 mg/kg (p = 0.12, p = 0.33, p = 0.26). CONCLUSION: Extract ethanol of basil leaves showed good results in lowering blood glucose and advanced glycation end products in diabetic rats.

Advanced glycation end products metabolism is modified by quantity and quality of dietary lipids in metabolic syndrome patients

2017 ◽  
Vol 263 ◽  
pp. e167 ◽  
Author(s):  
Javier Lopez-Moreno ◽  
Francisco Gomez-Delgad ◽  
Carolina Fernandez-Gandara ◽  
Antonio Camargo ◽  
Andrea Corina ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Advanced Glycation End Products ◽  
Dietary Lipids ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Potential effect of advanced glycation end products (AGEs) on spermatogenesis and sperm quality in rodents

2019 ◽  
Vol 10 (6) ◽  
pp. 3324-3333 ◽  
Author(s):  
Min-Chun Chen ◽  
Jer-An Lin ◽  
Hsin-Tang Lin ◽  
Sheng-Yi Chen ◽  
Gow-Chin Yen
Keyword(s):  
Advanced Glycation End Products ◽  
Sperm Quality ◽  
Potential Effect ◽  
Advanced Glycation ◽  
High Intake ◽  
Glycation End Products ◽  
End Products

High intake of advanced glycation end products (AGEs) impairs spermatogenesis and sperm quality in rodents.

scholarly journals Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Mohamed Haddad ◽  
Ines Knani ◽  
Hsan Bouzidi ◽  
Olfa Berriche ◽  
Mohamed Hammami ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Advanced Glycation End Products ◽  
Plasma Levels ◽  
Enzyme Linked Immunosorbent Assay ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Control Subjects ◽  
Glycation End Products ◽  
End Products ◽  
Carboxymethyl Lysine

Metabolic syndrome (MetS) is considered one of the most important public health problems. Several and controversial studies showed that the role of advanced glycation end products (AGEs) and their receptor in the development of metabolic syndrome and therapeutic pathways is still unsolved. We have investigated whether plasma pentosidine, carboxymethyl-lysine (CML), and soluble receptor for advanced glycation end products (sRAGE) levels were increased in patients with MetS and the effect of metformin in plasma levels of pentosidine, CML, and sRAGE. 80 control subjects and 86 patients were included in this study. Pentosidine, CML, and sRAGE were measured in plasma by enzyme-linked immunosorbent assay (ELISA). Plasma pentosidine, CML, and sRAGE levels were significantly increased in patients compared to control subjects (P<0.001,P<0.001, andP=0.014, resp.). Plasma levels of pentosidine were significantly decreased in patients who received metformin compared to untreated patients (P=0.01). However, there was no significant difference between patients treated with metformin and untreated patients in plasma CML levels. Plasma levels of sRAGE were significantly increased in patients who received metformin and ACE inhibitors (P<0.001andP=0.002, resp.). However, in a multiple stepwise regression analysis, pentosidine, sRAGE, and drugs treatments were not independently associated. Patients with metabolic syndrome showed increased levels of AGEs such as pentosidine and CML. Metformin treatment showed a decreased level of pentosidine but not of CML. Therapeutic pathways of AGEs development should be taken into account and further experimental andin vitrostudies merit for advanced research.

Sign in / Sign up

Export Citation Format

Share Document